Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany
- Sandoz inaugurates new antibiotic production plant in Austria and new biosimilar development center in Germany
- Investment of EUR 175 million reaffirms Sandoz commitment to long-term leadership in off-patent medicines
- New penicillin production process will significantly improve ecological footprint and help secure European-based supply
- Cutting-edge development hub will play key role in supporting long-term growth of leading biosimilar business
Basel – Sandoz, the global leader in generic and biosimilar medicines, has opened two new European facilities, in line with its ongoing plans to strengthen sustainable development and supply of critical medicines in Europe and beyond.
The inauguration of a new facility for production of penicillin at Kundl, Austria, and a new biosimilar development center in Holzkirchen, Germany, reaffirm the dual Sandoz commitment to ensuring sustainable access to quality antibiotics and spearheading development of biosimilars.
Sandoz has the only major remaining vertically-integrated production network for penicillins in Europe; penicillins are the leading category of antibiotics worldwide. The EUR 150 million Kundl investment, which includes a contribution of EUR 50 million from the Austrian federal government, represents a significant upgrade of penicillin API (active pharmaceutical ingredient) manufacturing.
Richard Saynor, CEO Sandoz said: "These investments strengthen our industrial presence in Europe, reinforce our commitment to environmental responsibility, and reaffirm our determination to be the world's leading and most valued generics and biosimilars company. Antibiotics are the backbone of modern medicine and the Kundl plant is a testament to the resilience of European manufacturing. The new development center in Holzkirchen will become a global hub for biosimilar expertise."
The EUR 25 million Holzkirchen investment will pave the way for the German site to become the leading Sandoz analytical characterization center for biosimilars.
The Austrian federal and Bavarian state governments have been highly supportive of these projects, recognizing their importance for ensuring availability of medicines and advancing medical research in Europe.
Latest news
IPCEI funding approval paves way for progress at bp’s Lingen green hydrogen project
bp’s 100MW industrial-scale green hydrogen project awarded funding, provided jointly by BMWK and Lower-Saxony Government, as part of the European IPCEI (Important Projects of Common European intere...
German and state governments grant funding for large hydrogen projects by RWE at Lingen, Germany
Electrolyser plant in Lingen and hydrogen storage facility in Epe to be funded with a total of 619 million euros Rostock electrolysis project with RWE participation to receive 199 million euros F...
Europe’s first hydrogen fuelled power plant supporting the UK’s decarbonisation at Essars refinery in Stanlow, UK
EET Hydrogen Power announces the development of Europe’s first 100% hydrogen fuelled power plant. Hydrogen fuelled power is an essential part of decarbonisation of industry and the power system in ...
Boehringer Ingelheim produces its own green energy in Ingelheim, Germany
German Vice Chancellor and Federal Minister of Economics Robert Habeck inaugurates new biomass power plant Ingelheim site can cover 95% of its energy needs from renewable sources New power plant ...